Skip to content
Parakho

Hikal Ltd

NSE HIKALBSE 524735hikal.com

Q1 FY27, unaudited

Revenue
₹402.80 Cr
Profit after tax
₹-7.40 Cr

As filed with the exchange, consolidated basis.

Statement of profit and loss

Figures in ₹ crore, reproduced from the results data files the company filed with NSE under Regulation 33 of the SEBI (LODR) Regulations. Nothing is restated, adjusted or estimated.

Statement of profit and loss, consolidated basis
₹ croreQ1 FY27vs a year agoFY26
Revenue from operations402.80+5.89%1,712.60
Other income1.80+80.00%12.30
Total income404.60+6.08%1,724.90
Employee benefit expense74.40+18.28%270.30
Finance costs14.90−12.87%62.10
Depreciation & amortisation42.70+8.38%163.80
Total expenses423.40+2.82%1,718.10
Profit before tax-9.90+67.43%-78.30
Tax expense-2.50+68.75%-29.50
Profit after tax-7.40+66.96%-48.80
Total comprehensive income-7.20+68.42%-51.20
Earnings per share
Earnings per share, basic₹-0.60₹-3.96
Earnings per share, diluted₹-0.60₹-3.96

Q1 FY27 — unaudited, from the company’s filing with NSE. Source

Q1 FY26, the year-ago base — unaudited, from the company’s filing with NSE. Source

FY26 — from the company’s filing with NSE. Source

Q1 FY27 results for every company Parakho holds

Earnings call

Q1 FY27

Hikal reported Q1 FY27 revenue of Rs 403 crores with an EBITDA margin of 9.2% and a net loss of Rs 7 crores, as the Pharmaceutical business grew year-on-year despite a planned shutdown for U.S. FDA remediation. Management said the Crop Protection business saw sequential volume improvement but continued pricing pressure from Chinese competition and higher raw material costs, while the Animal Health business delivered another quarter of demand-led growth. The company also commissioned a new Personal Care manufacturing line at Panoli and guided to full-year revenue growth of approximately 14% to 16% and EBITDA growth of 25% to 30% for FY27.

Generated by AI from the filed transcript; every statement on the full page carries its verbatim quote.

Read the full summary

Earlier calls: Q4 FY26 · All quarters

Filings

12 shown · 60 published by the exchange

BSE corporate announcements, classified by Parakho. The exchange’s own category is kept alongside our classification so a reclassification never rewrites history.

Industry

Healthcare › Pharmaceuticals

Classification as published by BSE.

Companies also in Pharmaceuticals, in alphabetical order

All 196 companies in Pharmaceuticals

Page generated from filings held to 07 Oct 2026.